Group One Trading
TRVI icon

Group One Trading’s Trevi Therapeutics TRVI Stock Holding History

Group One Trading’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$645K Buy
34,600
+12,000
+53% +$175K ﹤0.01% 3255
2026
Q1 		$270K Sell
22,600
-58,300
-72% -$653K ﹤0.01% 3883
2025
Q4 		$1.01M Sell
80,900
-105,700
-57% -$1.22M ﹤0.01% 2880
2025
Q3 		$1.71M Sell
186,600
-14,500
-7% -$109K ﹤0.01% 2470
2025
Q2 		$1.1M Buy
201,100
+142,100
+241% +$884K ﹤0.01% 2676
2025
Q1 		$371K Buy
59,000
+52,400
+794% +$250K ﹤0.01% 3395
2024
Q4 		$27.2K Buy
+6,600
New +$21.1K ﹤0.01% 5501

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Group One Trading's TRVI Position: Q2 2026 in Review

Group One Trading sold out of Trevi Therapeutics (TRVI) in Q2 2026, closing a stake of 25,930 shares — an estimated $377K sold.

Group One Trading first reported a position in TRVI in Q4 2024 and held it in 3 quarters. The position peaked at $369K in Q1 2025. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Group One Trading reported no remaining Trevi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Group One Trading sold 25,930 Trevi Therapeutics shares in Q2 2026, an estimated $377K.
  • Group One Trading first reported a position in Trevi Therapeutics in Q4 2024 and held it in 3 quarters.
  • Group One Trading's Trevi Therapeutics position peaked at $369K in Q1 2025.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.